Etiya Secures a Strategic Investment from Quebecor Media
AMSTERDAM, October 5, 2021 — Etiya, the leading Independent Software Provider, today announced that it…
AMSTERDAM, October 5, 2021 — Etiya, the leading Independent Software Provider, today announced that it…
USU Bot Universe combines the expertise of multiple chatbots for new complex application areas Möglingen,…
Private equity buyers’ share rises to 44 per cent of all deals London, UK –…
The award-winning technology cuts out the middle man by providing straightforward legal advice Bristol, UK;…
New Firebox M Series combines security, performance, flexibility and visibility for the WatchGuard Unified Security…
Elatec Receives Patent for USB Rotary Connector Munich – Elatec’s TWN4 USB Front Reader makes…
WBA cross-industry survey of service providers, technology vendors and enterprises demonstrates mass adoption of Wi-Fi…
OliveX and Hong Kong Premier League’s RCFC in Ground-Breaking Innovation for the Region 5 October…
Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S…
ORION CORPORATION PRESS RELEASE 5 October 2021 at 9.00 EEST Orion publishes Interim Report…
Leuven, BELGIUM, Boston, MA, US – 5 October, 2021 – 08.00 AM CET –…
OCREVUS (ocrelizumab) data to show sustained reduction in disability progression through 8 years for primary…
Potential Indication Expansion for Telix’s Core Kidney Cancer Theranostic Program MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05,…
PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Biophytis SA (NasdaqCM: BPTS, Euronext…
NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc…
Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens LEXINGTON, Mass., Oct….
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase…
Continuing filgotinib 200mg among induction non-responders at week 10 resulted in clinical benefits for ulcerative…
BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…